Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Director comp.

Oncology Institute, Inc. (DFPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Investor presentation
Docs: "1THE ONCOLOGY INSTITUTE OF HOPE"
08/08/2023 8-K Quarterly results
Docs: "The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance"
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "1/2 The Oncology Institute Announces Leadership Transition Dr. Daniel Virnich"
05/10/2023 8-K Quarterly results
Docs: "The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance"
03/27/2023 8-K Quarterly results
03/09/2023 8-K Quarterly results
Docs: "The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023"
12/01/2022 8-K Quarterly results
11/14/2022 8-K Investor presentation
Docs: "Investor Presentation November 2022 Disclaimer Forward Looking Statements Financial"
11/09/2022 8-K Quarterly results
Docs: "The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance"
09/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "The Oncology Institute Appoints Two New Board Members"
08/15/2022 8-K Investor presentation
Docs: "Investor Presentation August 2022 Disclaimer Forward Looking Statements This"
08/09/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
Docs: "The Oncology Institute Reports Second Quarter 2022 Financial Results and Reaffirms Full Year 2022 Guidance"
07/15/2022 8-K Quarterly results
05/11/2022 8-K Other Events  Interactive Data
05/10/2022 8-K Quarterly results
Docs: "The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 Guidance"
03/11/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
Docs: "The Oncology Institute Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Strong Growth Outlook for 2022"
03/07/2022 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/22/2021 8-K/A Director compensation was amended/approved
Docs: "Certificate of Designation of Series A Common Stock Equivalent Convertible Preferred Stock",
"0000001 SEE REVERSE FOR IMPORTANT NOTICE REGARDING OWNERSHIP AND TRANSFER RESTRICTIONS AND CERTAIN OTHER INFORMATION CUSIP SEE REVERSE FOR CERTAIN DEFINITIONS INCORPORATED UNDER THE LAWS OF THE PROVINCE OF ONTARIO, CANADA SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK SPECIMEN CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER FULLY PAID AND NON-ASSESSABLE SHARES OF SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK $0.0001 PAR VALUE, OF THE ONCOLOGY INSTITUTE CORP. transferable on the books of the Company in Person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Articles of Incorporation, as it may be amended, a...",
"AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT",
"ARTICLE I. PURPOSE The Plan’ s purpose is to enhance the Company’ s and its Related Entities’ ability to attract, retain and motivate persons who make important contributions to the Company or its Related Entities by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILITY Service Providers are eligible to be granted Awards under the Plan as determined by the Administrator from time to time, subject to the limitations described herein. ARTICLE III. ADMINISTRATION AND DELEGATION 3.1    Administration . The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, g...",
"ARTICLE I.",
"Exchange Agreement, by and among DFP Healthcare Acquisitions Corp., Deerfield Private Design Fund IV, L.P., Dererfield Partners, L./P. and DFP Sponsor LLC",
"Form of Indemnification Agreement",
"CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT THIS AMENDED AND RESTATED MANAGEMENT SERVICES AGREEMENT , dated January 12, 2021 and effective as of September 19, 2018, is by and between TOI Management, LLC, a Delaware limited liability company and The Oncology Institute CA, a Professional Corporation , a California professional corporation , for itself and on behalf of its subsidiaries . R E C I T A L S A. Management provides physician practice management services and has expertise in billing compliance programs and in related practice and other ancillary management and administrative activities for and on behalf o...",
"TOI PARENT, INC.",
"List of Subsidiaries"
11/18/2021 8-K Director compensation was amended/approved
Docs: "THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DFP HEALTHCARE ACQUISITIONS CORP. ***** DFP Healthcare Acquisitions Corp., a corporation organized and existing under the laws of the state of Delaware , does hereby certify as follows: 1. The original certificate of incorporation of the Corporation was filed with the Secretary of State of Delaware on November 1, 2019 . The name under which the Original Certificate of Incorporation was filed is “DFP Healthcare Acquisitions Corp.” 2. The Corporation’ s First Amended and Restated Certificate of Incorporation, which amended and restated the provisions of the Original Certificate of Incorporation, was duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, as amended from time ...",
"Amended & Restated Bylaws of The Oncology Institute, Inc.",
"ARTICLE I. PURPOSE The Plan’ s purpose is to enhance the Company’ s and its Related Entities’ ability to attract, retain and motivate persons who make important contributions to the Company or its Related Entities by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILITY Service Providers are eligible to be granted Awards under the Plan as determined by the Administrator from time to time, subject to the limitations described herein. ARTICLE III. ADMINISTRATION AND DELEGATION 3.1    Administration . The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, g...",
"ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: the Section 423 Component and the Non-Section 423 Component. The Section 423 Component is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code and shall be administered, interpreted and construed in a manner consistent with the requirements of Section 423 of the Code. The Non-Section 423 Component authorizes the grant of rights which need not qualify as rights granted pursuant to an “employee stock purchase plan” under Section 423 of the Code. Rights granted under the Non-Section 423 Component shall be granted pursuant to separate Offerings con...",
"TOI Parent, Inc.",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined balance sheet as of September 30, 2021 and the unaudited pro forma condensed combined statements of operations for the year ended December 31, 2020 and nine months ended September 30, 2021 present the combined financial information of DFP and TOI after giving effect to the Business Combination and related adjustments described in the accompanying notes. DFP and TOI are collectively referred to herein as the “Companies,” and the Companies, subsequent to the Business Combination, are referred to herein as the “Combined Company” or “New TOI.” The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X, as amend..."
10/22/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute"
10/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "1600. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE."
06/28/2021 8-K Director compensation was amended/approved
Docs: "Agreement and Plan of Merger, by and among DFP Healthcare Acquisitions Corp. Orion Merger Sub I, Inc., Orion Merger Sub II, LLC and TOI Parent Inc",
"Form of Subscription Agreement",
"Form of Deerfield Subscription Agreement",
"Stockholder Support Agreement, by and among DFP Healthcare Acquisitions Corp., TOI Parent Inc., DFP Sponsor LLC and the other signatories thereto",
"Company Support Agreement, by and among DFP Healthcare Acquisitions Corp., TOI Parent Inc. and the other signatories thereto",
"Consent and Waiver Letter, by and among DFP Healthcare Acquisitions Corp., DFP Sponsor LLC, Deerfield Private Design Fund IV, L.P. and Deerfield Partners, L.P"
06/28/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
04/28/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release"
03/19/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy